Abstract
The mitogen activated protein kinases-extracellular signal regulated kinases (MAPK-ERK) pathway is involved in regulation of multiple cellular processes including the cell cycle. In the present study using a Huh7 cell line Con1 with an HCV replicon, we have shown that the MAPK-ERK pathway plays a significant role in the modulation of HCV replication and protein expression and might influence IFN-α signalling. Epithelial growth factor (EGF) was able to stimulate ERK activation and decreased HCV RNA load while a MAPK-ERK pathway inhibitor U0126 led to an elevated HCV RNA load and higher NS5A protein amounts in Con1 cells. It could be further demonstrated that the inhibition of the MAPK-ERK pathway facilitated the translation directed by the HCV internal ribosome entry site. Consistently, a U0126 treatment enhanced activity of the HCV reporter replicon in transient transfection assays. Thus, the MAPK-ERK pathway plays an important role in the regulation of HCV gene expression and replication. In addition, cyclin-dependent kinases (CDKs) downstream of ERK may also be involved in the modulation of HCV replication since roscovitine, an inhibitor of CDKs had a similar effect to that of U0126. Modulation of the cell cycle progression by cell cycle inhibitor or RNAi resulted consistently in changes of HCV RNA levels. Further, the replication of HCV replicon in Con1 cells was inhibited by IFN-α. The inhibitory effect of IFN-α could be partly reversed by pre-incubation of Con-1 cells with inhibitors of the MAPK-ERK pathway and CDKs. It could be shown that the MAPK-ERK inhibitors are able to partially modulate the expression of interferon-stimulated genes.
References
Aktas H, Cai H, Cooper G M. 1997. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin d1 and the cdk inhibitor p27kip1. Mol Cell Biol, 17(7): 3850–3857.
Alter M J. 1997. Epidemiology of hepatitis c. Hepatology, 26(S3): 62S–65S.
Bartenschlager R. 2006. Hepatitis c virus molecular clones: From cdna to infectious virus particles in cell culture. Current Opinion in Microbiology, 9(4): 416–422.
Binder M, Kochs G, Bartenschlager R, et al. 2007. Hepatitis c virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy. Hepatology, 46(5): 1365–1374.
Broering R, Wu J, Meng Z, et al. 2008. Toll-like receptorstimulated non-parenchymal liver cells can regulate hepatitis c virus replication. J Hepatol, 48(6): 914–922.
Brunet A, Danie’ Le Roux, Lenorm P, et al. 1999. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. The EMBO Journal, 18(3): 664–674.
Chang Y, Lei Y, Wu W, et al. 2007. Effect of hepatitis c virus core protein on interferon-induced antiviral genes expression and its mechanisms. Virologica Sinica, 22(5): 274–379.
Choo Q L, Kuo G, Weinera J, et al. 1989. Isolation of a cdna clone derived from a blood-borne non-a, non-b viral hepatitis genome. Science, 244(4902): 359–362.
Cyert M S. 2001. Regulation of nuclear localization during signaling. J Biol Chem, 276(24): 20805–20808.
Fimia G M, Evangelisti C, Alonzi T, et al. 2004. Conventional protein kinase c inhibition prevents alpha interferon-mediated hepatitis c virus replicon clearance by impairing stat activation. J Virol, 78(23): 12809–12816.
Foy E, Li K, Wang C, et al. 2003. Regulation of interferon regulatory factor-3 by the hepatitis c virus serine protease. Science, 300(5622): 1145–1148.
Foy E, Li K, Sumpter R, Jr, et al. 2005. Control of antiviral defenses through hepatitis c virus disruption of retinoic acid-inducible gene-i signaling. Proc Natl Acad Sci U S A, 102(8): 2986–2991.
Frese M, Schwarzle V, Barth K, et al. 2002. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis c virus rnas. Hepatology, 35(3): 694–703.
Gretton S, Hughes M, Harris M. 2010. Hepatitis c virus rna replication is regulated by ras-erk signalling. J Gen Virol, 91(Pt 3): 671–680.
Guo J-T, Zhu Q, Seeger C. 2003. Cytopathic and noncytopathic interferon responses in cells expressing hepatitis c virus subgenomic replicons. J Virol, 77(20): 10769–10779.
Huang Y, Chen X C, Konduri M, et al. 2006. Mechanistic link between the anti-hcv effect of interferon gamma and control of viral replication by a ras-mapk signaling cascade. Hepatology, 43(1): 81–90.
Kawada M, Yamagoe S, Murakami Y, et al. 1997. Induction of p27kip1 degradation and anchorage independence by ras through the map kinase signaling pathway. Oncogene, 15(6): 629–637.
Krieger N, Lohmann V, Bartenschlager R. 2001. Enhancement of hepatitis c virus rna replication by cell culture-adaptive mutations. J Virol, 75(10): 4614–4624.
Li K, Foy E, Ferreon J C, et al. 2005. Immune evasion by hepatitis c virus ns3/4a protease-mediated cleavage of the toll-like receptor 3 adaptor protein trif. Proc Natl Acad Sci U S A, 102(8): 2992–2997.
Lindenbach B D, Evans M J, Syder a J, et al. 2005. Complete replication of hepatitis c virus in cell culture. Science, 309(5734): 623–626.
Lohmann V, Ouml, Rner F, et al. 1999. Replication of subgenomic hepatitis c virus rnas in a hepatoma cell line. Science, 285(5424): 110–113.
Maccorkle R, Tan T-H. 2005. Mitogen-activated protein kinases in cell-cycle control. Cell Biochemistry and Biophysics, 43(3): 451–461.
Macdonald A, Chan J K Y, Harris M. 2005. Perturbation of epidermal growth factor receptor complex formation and ras signalling in cells harbouring the hepatitis c virus subgenomic replicon. J Gen Virol, 86(4): 1027–1033.
Macdonald A, Crowder K, Street A, et al. 2003. The hepatitis c virus non-structural ns5a protein inhibits activating protein-1 function by perturbing ras-erk pathway signaling. J Biol Chem, 278(20): 17775–17784.
Mankouri J, Griffin S, Harris M. 2008. The hepatitis c virus non-structural protein ns5a alters the trafficking profile of the epidermal growth factor receptor. Traffic, 9(9): 1497–1509.
Mannova P, Beretta L. 2005. Activation of the n-ras-pi3k-aktmtor pathway by hepatitis c virus: Control of cell survival and viral replication. J Virol, 79(14): 8742–8749.
Meloche S, Pouyssegur J. 2007. The erk1//2 mitogen-activated protein kinase pathway as a master regulator of the g1-to s-phase transition. Oncogene, 26(22): 3227–3239.
Meylan E, Curran J, Hofmann K, et al. 2005. Cardif is an adaptor protein in the rig-i antiviral pathway and is targeted by hepatitis c virus. Nature, 437(7062): 1167–1172.
Murata T, Hijikata M, Shimotohno K. 2005. Enhancement of internal ribosome entry site-mediated translation and replication of hepatitis c virus by pd98059. Virology, 340(1): 105–115.
Ndjomou J, Park I W, Liu Y, et al. 2009. Up-regulation of hepatitis c virus replication and production by inhibition of mek/erk signaling. PLoS One, 4(10): e7498.
Nelson H B, Tang H. 2006. Effect of cell growth on hepatitis c virus (hcv) replication and a mechanism of cell confluence-based inhibition of hcv rna and protein expression. J Virol, 80(3): 1181–1190.
Schaeffer H J, Weber M J. 1999. Mitogen-activated protein kinases: Specific messages from ubiquitous messengers. Mol Cell Biol, 19(4): 2435–2444.
Seeff L B. 1997. Natural history of hepatitis c. Hepatology, 26(S3): 21S–28S.
Street A, Macdonald A, Crowder K, et al. 2004. The hepatitis c virus ns5a protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem, 279(13): 12232–12241.
Sumpter R, Jr, Loo Y M, Foy E, et al. 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis c virus rna replication through a cellular rna helicase, rig-i. J Virol, 79(5): 2689–2699.
Takuwa N, Takuwa Y. 1997. Ras activity late in g1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into s phase in growth factor-stimulated nih 3t3 fibroblasts. Mol Cell Biol, 17(9): 5348–5358.
Tong M J, El-Farra N S, Reikes a R, et al. 1995. Clinical outcomes after transfusion-associated hepatitis c. N Engl J Med, 332(22): 1463–1466.
Trujillo-Murillo K, Rincon-Sancheza R, Martinez-Rodriguez H, et al. 2008. Acetylsalicylic acid inhibits hepatitis c virus rna and protein expression through cyclooxygenase 2 signaling pathways. Hepatology, 47(5): 1462–1472.
Wakita T, Pietschmann T, Kato T, et al. 2005. Production of infectious hepatitis c virus in tissue culture from a cloned viral genome. Nat Med, 11(7): 791–796.
Yokota T, Sakamoto N, Enomoto N, et al. 2003. Inhibition of intracellular hepatitis c virus replication by synthetic and vector-derived small interfering rnas. EMBO Rep, 4(6): 602–608.
Zhong J, Gastaminza P, Cheng G, et al. 2005. Robust hepatitis c virus infection in vitro. Proc Natl Acad Sci USA, 102(26): 9294–9299.
Author information
Authors and Affiliations
Corresponding author
Additional information
Foundation items: Partly supported by a joint grant of Chinese Academy of Science and Deutsche Akademische Austausch Dienst, and the the National Basic Research Priorities Program of China (2009CB522501, 2005CB522901, 2007CB512901).
Rights and permissions
About this article
Cite this article
Pei, R., Zhang, X., Xu, S. et al. Regulation of Hepatitis C virus replication and gene expression by the MAPK-ERK pathway. Virol. Sin. 27, 278–285 (2012). https://doi.org/10.1007/s12250-012-3257-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12250-012-3257-6